Payment overview · 2025
General Payments
$648.34
34 reported records · 14 companies
Healthcare provider profile · identity verified
Patrick L Godwin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROXBORO, NC · NPI 1164483483
Verified facts
What the public records show
CMS Open Payments records show Patrick L Godwin, MD received $648.34 in general payments during 2025 across 34 reported records.
ABBVIE INC. accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 407 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $136.49 | 21.1% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $106.45 | 16.4% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $69.49 | 10.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.52 | 8.4% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $50.01 | 7.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $43.91 | 6.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.18 | 5.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.10 | 5.9% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.17 | 3.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.91 | 3.7% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $17.71 | 2.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.96 | 2.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.97 | 2.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.47 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $648.34 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $113.40 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $72.64 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $72.64 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.58 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.85 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $50.01 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.57 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.87 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.10 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $37.59 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 115 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 407 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
115 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
42 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
115 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
407 | 76 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 775 | 211 |
| Atorvastatin Calcium | Atorvastatin Calcium | 765 | 212 |
| Levothyroxine Sodium | Levothyroxine Sodium | 691 | 173 |
| Lisinopril | Lisinopril | 589 | 167 |
| Metformin Hcl | Metformin Hcl | 562 | 167 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 548 | 159 |
| Losartan Potassium | Losartan Potassium | 521 | 148 |
| Carvedilol | Carvedilol | 477 | 137 |
| Pantoprazole Sodium | Pantoprazole Sodium | 477 | 133 |
| Furosemide | Furosemide | 475 | 137 |
| Hydrochlorothiazide | Hydrochlorothiazide | 459 | 131 |
| Ozempic | Semaglutide | 407 | 76 |
| Omeprazole | Omeprazole | 401 | 113 |
| Gabapentin | Gabapentin | 393 | 108 |
| Escitalopram Oxalate | Escitalopram Oxalate | 343 | 85 |
| Oxycodone Hcl | Oxycodone Hcl | 325 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 322 | 95 |
| Pravastatin Sodium | Pravastatin Sodium | 316 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 284 | 90 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 283 | 39 |
| Simvastatin | Simvastatin | 283 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 280 | 81 |
| Eliquis | Apixaban | 255 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 220 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 219 | 88 |
| Alendronate Sodium | Alendronate Sodium | 209 | 58 |
| Farxiga | Dapagliflozin Propanediol | 200 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 55 |
| Potassium Chloride | Potassium Chloride | 188 | 58 |
| Allopurinol | Allopurinol | 154 | 45 |
| Sertraline Hcl | Sertraline Hcl | 154 | 42 |
| Ibuprofen | Ibuprofen | 153 | 47 |
| Pregabalin | Pregabalin | 146 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 140 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 130 | 27 |
| Alprazolam | Alprazolam | 129 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 125 | 42 |
| Metformin Hcl Er | Metformin Hcl | 122 | 34 |
| Mirtazapine | Mirtazapine | 121 | 31 |
| Trazodone Hcl | Trazodone Hcl | 121 | 34 |
| Prednisone | Prednisone | 118 | 50 |
| Jardiance | Empagliflozin | 115 | 28 |
| Spironolactone | Spironolactone | 115 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 114 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 108 | 27 |
| Tramadol Hcl | Tramadol Hcl | 108 | 36 |
| Meloxicam | Meloxicam | 104 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 104 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 102 | 24 |
| Lorazepam | Lorazepam | 99 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 99 | 27 |
| Montelukast Sodium | Montelukast Sodium | 96 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 93 | 40 |
| Clonazepam | Clonazepam | 91 | 18 |
| Famotidine | Famotidine | 87 | 26 |
| Azithromycin | Azithromycin | 84 | 71 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 82 | 16 |
| Linzess | Linaclotide | 82 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 25 |
| Ramipril | Ramipril | 78 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 78 | 25 |
| Warfarin Sodium | Warfarin Sodium | 78 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 77 | 61 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 52 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 20 |
| Ezetimibe | Ezetimibe | 69 | 17 |
| Mounjaro | Tirzepatide | 67 | 12 |
| Memantine Hcl | Memantine Hcl | 65 | 17 |
| Nitroglycerin | Nitroglycerin | 61 | 27 |
| Finasteride | Finasteride | 60 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 24 |
| Levofloxacin | Levofloxacin | 57 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 53 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 45 |
| Valacyclovir | Valacyclovir Hcl | 53 | 23 |
| Febuxostat | Febuxostat | 50 | 11 |
| Glipizide Er | Glipizide | 49 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 40 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 47 | 12 |
| Meclizine Hcl | Meclizine Hcl | 47 | 26 |
| Topiramate | Topiramate | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 14 |
| Ondansetron Odt | Ondansetron | 46 | 21 |
| Fluconazole | Fluconazole | 45 | 33 |
| Promethazine Hcl | Promethazine Hcl | 45 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 43 | 13 |
| Klor-Con M20 | Potassium Chloride | 43 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 43 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 25 |
| Nystatin | Nystatin | 42 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 42 | 37 |
| Clarithromycin | Clarithromycin | 41 | 34 |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 12 |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | 11 |
| Glimepiride | Glimepiride | 40 | 14 |
| Diazepam | Diazepam | 39 | 12 |
| Celecoxib | Celecoxib | 38 | 13 |
| Torsemide | Torsemide | 38 | 15 |
| Sucralfate | Sucralfate | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Colchicine | Colchicine | 34 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 11 |
| Estradiol | Estradiol | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 15 |
| Epinephrine | Epinephrine | 30 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 22 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 23 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Ibu | Ibuprofen | 21 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Mysoline | Primidone | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $648.34 · 34 records | ABBVIE INC. | CAPLYTA, CAPVAXIVE, GARDASIL 9, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, NEFFY, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, ROTATEQ, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, VAXELIS, VAXNEUVANCE, VRAYLAR, Wegovy, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error